LeonaBio (LONA) Stock Forecast: StockMap's 2-Week Call

LONA stock forecast: StockMap's model calls LeonaBio Strong Underperform for the two weeks after the Nov 19 close: it expects LONA to trail the growth index. It is a call on the gap, not a price target. Right in 5 of 6 two-week windows on LONA since Aug 21; by chance, a call on the same dates was right 59% of the time.

LeonaBio last closed at $2.46, -7.17% on the session.

Against the IVW growth benchmark the position is -4.84% over the forecast window.

LeonaBio's market cap is $32.17M as of November 19, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -51 (behind).

Where LONA sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

49 daily calls for LONA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks LeonaBio in the 2nd percentile on return on equity, where 100 is best.

LeonaBio is classified under Health Care / Pharmaceuticals.

StockMap tracks LeonaBio as the 116th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.

On that composite LeonaBio ranks 128th of 153 in the group, against a group median of -0.36.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

LeonaBio (LONA) — StockMap 2-week forecast & tracked accuracy